SS
ACHL

SBI Securities’s Achilles Therapeutics ACHL Stock Holding History

SBI Securities’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-196
Closed -$290 – 4277
2025
Q1 		$290 Sell
196
-126
-39% -$164 ﹤0.01% 3082
2024
Q4 		$367 Buy
+322
New +$332 ﹤0.01% 3009

Other funds holding ACHL

RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

SBI Securities's ACHL Position: Q2 2025 in Review

SBI Securities sold out of Achilles Therapeutics (ACHL) in Q2 2025, closing a stake of 196 shares — an estimated $290 sold.

SBI Securities first reported a position in ACHL in Q4 2024 and held it in 2 quarters. The position peaked at $367 in Q4 2024. 2 funds tracked by Wall St. Rank hold ACHL as of Q2 2025.

  • SBI Securities reported no remaining Achilles Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SBI Securities sold 196 Achilles Therapeutics shares in Q2 2025, an estimated $290.
  • SBI Securities first reported a position in Achilles Therapeutics in Q4 2024 and held it in 2 quarters.
  • SBI Securities's Achilles Therapeutics position peaked at $367 in Q4 2024.
  • 2 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q2 2025.

Based on SBI Securities's 13F filing for Q2 2025, filed 8 Aug 2025.